Acurx reports Q4/FY2021 results; Phase 2b enrollment ongoing for ibezapolstat

Acurx Pharmaceuticals, Inc.

R&D expense FY2021: $2.0M (vs $2.2M in 2020); Q4 2021: $0.7M (vs $0.5M).
G&A expense FY2021: $10.8M (vs $2.4M) due to stock-based compensation and professional fees.
Phase 2a trial for C. difficile infection achieved 100% clinical cure and sustained cure with ibezapolstat.
Phase 2b enrollment expected to complete in H2 2022, comparing ibezapolstat to vancomycin.
New microbiome study with University of Houston comparing ibezapolstat to other CDI antibiotics anticipated H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.